Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer

Launched by FONDAZIONE IRCCS POLICLINICO SAN MATTEO DI PAVIA · May 18, 2022

Keywords

ClinConnect Summary

This clinical trial is studying whether giving patients with metastatic non-small cell lung cancer special oral nutritional supplements can help improve the effectiveness of their immunotherapy treatment. Immunotherapy is a type of cancer treatment that helps the immune system fight cancer. The trial aims to see if these supplements, which are enriched with nutrients that support the immune system, can enhance the benefits of the immunotherapy that patients are already receiving.

To participate in this trial, patients need to be diagnosed with metastatic non-small cell lung cancer and be starting their first treatment with immunotherapy. They should also be willing to take the nutritional supplements and have a life expectancy of at least six months. Participants will receive nutritional counseling along with their treatment. It's important to note that patients who are younger than 18, cannot provide consent, or are already receiving certain types of artificial nutrition support are not eligible for this study. Overall, this trial is looking for ways to improve cancer treatment outcomes through better nutrition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed histological diagnosis of metastatic non-small cell lung cancer (both squamous and non-squamous histology);
• • First-line treatment with immunotherapy (alone or in combination with chemotherapy) for metastatic disease by investigators' choice within the framework of good clinical practice and in agreement with current guidelines;
• • Will to participate by providing written informed consent;
• • Availability to administer oral supplements and immunotherapy with or without chemotherapy;
• • Eastern Cooperative Oncology Group Performance Status ≤ 2;
• • Life expectancy ≥ 6 months.
• Exclusion Criteria:
• • Age \< 18 years;
• • Inability to sign an informed consent;
• • Indication to or ongoing artificial nutrition support (totally compromised spontaneous food-intake) and incapacity or unavailability to consume oral nutritional supplements